Source: Annual Congress 2011 - Genetics of airway diseases and treatment
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
X. Wang, X. Zhao, W. Wu, Z. Gao, J. Wu, D. H. Garfield, D. Lu, C. Bai (Shanghai, China; San Diego, La Jolla, United States Of America). Predictive role of MMP-2 genetic variants on severe hematologic toxicity of NSCLC patients treated with first-line, platinum-based chemotherapy. Eur Respir J 2011; 38: Suppl. 55, 445

Member's Comments

No comment yet.

Related content which might interest you: Single agent gemcitabine or docetaxel in the second-line therapy for patients with non-small cell lung cancer previously treated with platin-based chemotherapy Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 A phase II trial of lipoplatin and gemcitabine in patients with NSCLC previously treated with platinum-based chemotherapy Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 Evaluation of outpatient infections in lung cancer patients treated with chemotherapy and/or radiotherapy Source: Annual Congress 2012 - Screening, diagnosis, staging and treatment strategies for lung cancer Year: 2012 Thromboembolic events in lung cancer patients treated with platinum-based chemotherapy Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology Year: 2019 Short-term efficacy of advanced NSCLC patients receiving anlotinib hydrochloride as the first and second-line treatment Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 Histology as a potential clinical predictor of outcome in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine and mitomycin (VM) combination chemotherapy Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Assessment of lung cancer related symptoms and chemotherapy related side effects in a group of patients with advanced lung cancer receiving palliative chemotherapy Source: Eur Respir J 2006; 28: Suppl. 50, 752s Year: 2006 Neoadjuvant chemotherapy for NSCLC, lung function and surgical therapy – which is their connection? Source: International Congress 2019 – Lung function testing: from experimental investigations to clinical applications Year: 2019 Bevacizumab shows survival benefit for non-small lung cancer patients who received subsequent pemetrexed treatment but not had a therapeutic effect in clinical practice Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Docetaxel as second-line chemotherapy (CT) in advanced non small cell lung cancer(NSCLC) patients (pts): does it really work? Source: Eur Respir J 2003; 22: Suppl. 45, 31s Year: 2003 Impact of neoadjuvant therapies on surgical indications and early postoperative outcome Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts Year: 2005 What outcome after the prescription of neoadjuvant chemotherapy in lung cancer? Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011 Adjuvant and neoadjuvant therapy in nonsmall cell lung cancer (NSCLC) Source: Annual Congress 2006 - Clinical year in review Year: 2006 Adjuvant therapy in NSCLC Source: Annual Congress 2007 - Clinical year in review Year: 2007 Definitive radiation therapy for elderly patients with stage III NSCLC not candidates for combined chemoradiation Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Phase I/II study of biweekly docetaxel/cisplatin with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer Source: Annual Congress 2005 - Chemotherapy and palliative care Year: 2005 The effectiveness of pegfilgrastim in preventing leucopenia in patients with lung cancer under chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 77s Year: 2005 Efficacy and safety of amurubicin (AMR) for the elderly with refractory relapse small cell lung cancer (SCLC) who had previous treatment Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010